Applications of (4R,6R)-Tert-Butyl-6-Cyanomethyl-2,2-Dimethyl-1,3-Dioxane-4-Acetate in Industrial Manufacturing

As the original manufacturer of (4R,6R)-Tert-Butyl-6-Cyanomethyl-2,2-Dimethyl-1,3-Dioxane-4-Acetate, we focus on its validated industrial roles, particularly in high-precision pharmaceutical synthesis and advanced chemical intermediates. The following sections detail critical downstream application scenarios with precise technical context for manufacturers seeking reliable formulation, compliance, and production details.

1. Chiral Intermediate for Antidiabetic Drug Synthesis

Pharmaceutical companies utilize this compound as a stereoselective intermediate in the synthesis of DPP-4 inhibitor active pharmaceutical ingredients (APIs), most notably during the assembly of gliptin-class oral antidiabetic agents. The chirality and protecting groups support the construction of complex molecules while meeting stringent regulatory expectations. Manufacturers integrate this intermediate at pivotal points requiring high chiral fidelity, ensuring downstream APIs meet international pharmacopoeial quality.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• US FDA 21 CFR Part 211
• EU GMP EudraLex Vol 4
• Japanese Pharmacopeia (JP) requirements for intermediates

Typical usage ratio

• Ranges from 0.95 to 1.05 molar equivalents in API route schemes, optimized via chiral purity and yield data on target batch scales

Downstream process integration

• Introduced post-initial condensation step, often before enantioselective cyclization or hydrolysis reactions; handled in multi-step organic synthesis under controlled, validated environments

Final product types

• Sitagliptin, Saxagliptin, Vildagliptin, and other gliptin-class APIs and their intermediates

2. Advanced Building Block in Custom Peptide Synthesis

Custom peptide manufacturers select this cyano-protected dioxane derivative as a chiral auxiliary or masking group for site-specific modification during the stepwise elongation of synthetic peptides. The compound helps maintain stereochemical integrity and targets selective deprotection, allowing precise insertion in peptide backbones while minimizing epimerization risks.

Industry compliance standards

• ISO 13485:2016 Quality Management for Medical Devices (when used in therapeutic peptide production)
• USP <1047> Good Manufacturing Practices for Bulk Pharmaceutical Excipients
• REACH Regulation (EC 1907/2006) for chemical handling in peptide synthesis
• Pharmaceutical Inspection Convention (PIC/S) Guidelines

Typical usage ratio

• Addition of 1.2 to 1.5 molar equivalents relative to the specific amino acid or intermediate residue, fine-tuned to maintain desired selectivity and cleavage profiles depending on chain length

Downstream process integration

• Loaded after Boc/Fmoc deprotection cycles as a masking reagent, followed by selective removal or transformation at key assembly steps before final deprotection and purification

Final product types

• Therapeutic peptides, diagnostic peptide probes, peptide vaccine subunits

3. Fine Chemical Intermediate for Agrochemical Active Ingredient Synthesis

Agrochemical formulators deploy this dioxane-based ester as an enantioselective intermediate when constructing certain nitrile-containing herbicides or insecticide active ingredients, where precise control over functional group addition and chiral centers greatly impacts biological activity. Batch protocols commonly require integration at bond-forming or asymmetric alkylation stages.

Industry compliance standards

• FAO/WHO Specifications for Plant Protection Products
• OECD Principles of Good Laboratory Practice (GLP) for chemical synthesis
• EU Regulation (EC) No 1107/2009 for plant protection products authorization
• ISO 9001:2015 for quality management during scale-up

Typical usage ratio

• 0.8–1.2 molar equivalents depending on target active loading and reaction pathway; adjusted to maximize isomeric enrichment and reduce waste in pilot and production scale manufacturing

Downstream process integration

• Fed into key asymmetric synthesis stages, typically at the stage of generating cyanomethylated or esterified core moieties before final formulation of the active ingredient

Final product types

• Nitrile-based herbicide actives, chiral insecticides, specialty agrochemical intermediates

4. Specialty Intermediate for Chiral Ligand Production

Makers of advanced catalysts and ligands for industrial asymmetric hydrogenation often apply this acetate as a starting material for creating highly selective chiral ligands. Its rigid bicyclic structure and defined stereochemistry enable downstream synthesis of phosphine or nitrogen ligands tailored for large-scale homogeneous catalysis in pharmaceutical and specialty chemical manufacturing.

Industry compliance standards

• ISO 9001:2015 for chemical manufacturing quality systems
• REACH Regulation (EC 1907/2006) for registered industrial intermediates
• Responsible Care® Management Systems (International Council of Chemical Associations)
• Internal audit protocols for traceability in catalyst supply chains

Typical usage ratio

• Typically 1.0 molar equivalent per target ligand precursor; ratio optimized in lab or pilot synthesis based on desired ligand yield and purity

Downstream process integration

• Serves as an early-stage intermediate, functionalized via selective oxidation, alkylation, or coupling to produce bulk chiral ligand molecules; further processed by coordination with transition metals

Final product types

• Chiral phosphine ligands, asymmetric hydrogenation catalysts, P,N-ligand building blocks for pharmaceutical catalysis